Top 5 Stocks to Buy Now
→ 3 Wall St. Legends Have Same Dark Prediction for June 29th (From TradeSmith) (Ad)tc pixel Free NAMSW Stock Alerts

NewAmsterdam Pharma (NAMSW) Competitors

NewAmsterdam Pharma logo
$21.42 +0.02 (+0.09%)
As of 06/24/2026 02:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NAMSW vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

Should you buy NewAmsterdam Pharma stock or one of its competitors? MarketBeat compares NewAmsterdam Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NewAmsterdam Pharma include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). These companies are all part of the "biotechnology" industry.

How does NewAmsterdam Pharma compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
NewAmsterdam Pharma$22.57MN/AN/AN/AN/A

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat NewAmsterdam Pharma's score of 1.44 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
NewAmsterdam Pharma Positive

Summary

NewAmsterdam Pharma beats 60 Degrees Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Alpha Tau Medical?

NewAmsterdam Pharma (NASDAQ:NAMSW) and Alpha Tau Medical (NASDAQ:DRTSW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
Alpha Tau Medical N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$22.57MN/AN/AN/AN/A
Alpha Tau MedicalN/AN/AN/AN/AN/A

In the previous week, Alpha Tau Medical had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for Alpha Tau Medical and 2 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.44 beat Alpha Tau Medical's score of 0.96 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company Overall Sentiment
NewAmsterdam Pharma Positive
Alpha Tau Medical Positive

Summary

NewAmsterdam Pharma beats Alpha Tau Medical on 2 of the 3 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Apollomics?

Apollomics (NASDAQ:APLMW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

In the previous week, Apollomics and Apollomics both had 2 articles in the media. NewAmsterdam Pharma's average media sentiment score of 1.44 beat Apollomics' score of 0.94 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Positive
NewAmsterdam Pharma Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
NewAmsterdam Pharma$22.57MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

Summary

NewAmsterdam Pharma beats Apollomics on 2 of the 2 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to BioVie?

BioVie (NASDAQ:BIVIW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

In the previous week, BioVie and BioVie both had 2 articles in the media. NewAmsterdam Pharma's average media sentiment score of 1.44 beat BioVie's score of 0.94 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Positive
NewAmsterdam Pharma Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
NewAmsterdam Pharma$22.57MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

Summary

NewAmsterdam Pharma beats BioVie on 2 of the 2 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIOW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$16.57KN/AN/AN/AN/A
NewAmsterdam Pharma$22.57MN/AN/AN/AN/A

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 2 articles in the media. NewAmsterdam Pharma's average media sentiment score of 1.44 beat Cardio Diagnostics' score of 1.43 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Cardio Diagnostics Positive
NewAmsterdam Pharma Positive

Company Net Margins Return on Equity Return on Assets
Cardio DiagnosticsN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

Summary

NewAmsterdam Pharma beats Cardio Diagnostics on 2 of the 2 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAMSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAMSW vs. The Competition

Export
MetricNewAmsterdam PharmaBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$482.48M$6.61B$12.27B
Dividend YieldN/A3.86%2.67%5.90%
P/E RatioN/A3.1825.7623.97
Price / SalesN/A7,163.00558.1698.02
Price / CashN/A13.1346.3353.91
Price / BookN/A90.6410.716.32
Net IncomeN/A-$96.07M$3.57B$337.22M
7 Day PerformanceN/A1.74%0.79%-1.25%
1 Month Performance-11.71%0.51%0.21%-0.63%
1 Year Performance169.43%70.85%30.83%27.95%

NewAmsterdam Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAMSW
NewAmsterdam Pharma
N/A$21.42
+0.1%		N/A+133.6%$0.00$22.57MN/A29
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
-7.1%		N/A-40.1%$0.00$1.00MN/A2
DRTSW
Alpha Tau Medical
N/A$1.89
-3.1%		N/A+913.3%$0.00N/AN/A80
APLMW
Apollomics
N/A$0.01
-10.3%		N/A-61.0%$0.00$8.50MN/A59
BIVIW
BioVie
N/A$0.33
+6.9%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NAMSW) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
3 Wall St. Legends Have Same Dark Prediction for June 29th
Three Wall Street legends are pointing to the same date - June 29th - as a potential turning point driven by a...
TradeSmith | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO “cancelled”?
SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...
InvestorPlace | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
The EPA just put a kill switch on Elon’s empire
A federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...
Behind the Markets | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Quick favor to ask you
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel